Genelux Corporation Common Stock Cash Flow Conversion Efficiency
Genelux Corporation Common Stock cash flow conversion efficiency. Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.264x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($22.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genelux Corporation Common Stock (2019–2025)
Cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2025. This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genelux Corporation Common Stock stock price for real-time trading data and today's change.
Genelux Corporation Common Stock Cash Flow Conversion Ratio Explained
Genelux Corporation Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency. Also see market value of Genelux Corporation Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DeFi Development Corp.
NASDAQ:DFDV
|
-0.963x |
|
Apetit Oyj
HE:APETIT
|
0.118x |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
N/A |
|
IF Bancorp Inc
NASDAQ:IROQ
|
0.018x |
|
Paseco Co. Ltd
KQ:037070
|
-0.036x |
|
Ampire Co Ltd
TWO:8049
|
0.048x |
|
Bien Sparebank ASA
OL:BIEN
|
0.207x |
|
Cj Corp Pref
KO:001045
|
0.099x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2025. Review Genelux Corporation Common Stock (GNLX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.54 Million | $-25.27 Million | -2.189x | -170.91% |
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more